Pick the Slot Before the Category Picks One for You

Medtronic agreed to spend $650 million in cash on SPR Therapeutics on May 20, closing the third leg of a $1.78 billion 2026 buying run inside chronic pain neuromodulation, per the Medtronic newsroom release. Boston Scientific closed its own $533 million Nalu Medical acquisition earlier this year, per the Boston Scientific newsroom. Nevro built the AI overlay slot the prior year. Three slots inside one category, three different acquirers, three different decisions about which shelf to own. Understanding the market is only part of the job. Making money, building systems, and getting to where you want to go — those are the problems The Build exists to help you think through, and the structural question that runs through all three is the one the new entrant in the category did not get a chance to answer. Pick the slot before the category picks one for you, or be priced as whatever is left over after the strategics decide where you fit.

Most Founders Wait for the Market to Tell Them Where They Fit

The default first-time founder picks a product, ships the launch, and lets the category sort out where the company sits inside it. The build-phase logic is that the device or the software is what defines the slot, and the slot will eventually become legible once enough customers, payers, and partners have weighed in on the product. The cost of that logic is that by the time the slot is legible, the strategics have already drawn the shelves around the company. The new entrant who started with a technically interesting device and an unspecified slot ends up positioned against whatever incumbent shelf the market eventually slotted the device into, and the comparable the buy-side reads is the incumbent the device most resembles rather than the slot the company actually wanted to compete inside.

The version of the business that compounds through that environment is the one that picks the slot first, before the engineering decisions are committed and before the launch documents are drafted. The work is to map the existing portfolios in the category, identify the structural gaps the incumbents cannot close from inside their current architectures, and pick the gap the company is going to occupy. The engineering, regulatory, and commercial plan all get sized against that gap. The product the company eventually ships is shaped by the slot the company picked, not the other way around. The cost of that discipline is real at the build-phase stage. The company has to delay the engineering plan until the slot is settled, and most founders find that delay psychologically uncomfortable. The return on that discipline is that the company walks into every commercial and strategic conversation with a coherent story about why the slot exists, why the incumbents cannot fill it, and how the company’s architecture proves both points at once.

The chronic pain category in May 2026 is the case study. The three strategics have now closed the three obvious slots. The new entrant who picked a slot first now has a defensible story about why none of the three incumbents can reach the pocket the company occupies. The new entrant who picked a device first is now competing against whichever incumbent shelf the market has decided the device most resembles.

Three Categories of Slot Decision Worth Studying

The first category is the step-down slot. Medtronic’s SPR acquisition is the example. The company that owns the permanent implanted product expands the shelf to include the temporary therapy that sits in front of the permanent implant, capturing the referral flow before the patient enters the implant pathway. The slot decision is about which step of the patient journey the company is going to own that the incumbent permanent-product company cannot easily reach. The same logic applies to defense hardware founders building consumable layers in front of the platform contract, to climate hardware founders building service layers in front of the asset, and to industrial robotics founders building integration layers in front of the robot fleet.

The second category is the form-factor slot. Boston Scientific’s Nalu acquisition is the example. The company that owns the large-format implanted product extends the shelf to include the miniaturized version that fits anatomies or use cases the large format cannot reach. The slot decision is about which physical or operational constraint the incumbent product cannot satisfy and the new architecture can. The same logic applies to physical AI founders building smaller robots for use cases the large humanoid cannot enter, to climate hardware founders building distributed installations where centralized infrastructure cannot reach, and to diagnostics founders building point-of-care assays where centralized labs cannot deliver the time-to-result the clinical decision requires.

The third category is the algorithmic slot. Nevro’s closed-loop AI overlay is the example. The company that cannot win on form factor or installed base differentiates on the layer of the product where the incumbent’s prior architecture is hardest to retrofit, and uses that algorithmic differentiation as the structural moat. The slot decision is about which software, data, or learning layer the incumbent cannot quickly retrofit into existing devices. The same logic applies to defense hardware founders building autonomy stacks on top of existing platforms, to industrial founders building optimization software on top of installed factory floors, and to medtech founders building AI overlays for installed surgical and diagnostic platforms.